ResMed head passes mantle to son
This article was originally published in Clinica
Executive Summary
Respiratory disorder therapy firm ResMed's founder, chairman and CEO Dr Peter Farrell is passing the role of chief executive over to his son Michael Farrell, who is currently head of the firm's Americas operations. Mr Farrell Jnr has been at ResMed since 2000 and has held a number of senior sales and business development roles. Robert Douglas, the current chief operating officer, will assume the additional responsibility of president. Dr Farrell will remain executive chairman and work with his son and Mr Douglas on an as-needed basis through the end of 2013, after which he will become non-executive chairman. Mr Farrell's existing role of president, Americas, will be taken up by ResMed's current chief strategy officer and president of ventures and initiatives strategic unit, Dr Jim Hollingshead.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.